A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Latest Information Update: 26 Aug 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Selinexor (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Karyopharm Therapeutics
- 23 Aug 2024 Status changed from active, no longer recruiting to discontinued.
- 01 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.
- 31 Aug 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Sep 2023.